Texas Retina’s Robert C. Wang, MD, was interviewed about his presentation at the Association for Research in Vision and Ophthalmology (ARVO) 2025 Meeting for an episode of the New Retina Radio podcast released on May 22, 2025.
In it, he shares top line results from the Phase IIb ODYSSEY study of suprachoroidally administered CLS-AX, a tyrosine kinase inhibitor (TKI), for the treatment of neovascular (wet) age-related macular degeneration. Key study findings included:
- Two-thirds of participants dosed with CLS-AX reached six months without additional treatment.
- CLS-AX reduced injection frequency by 84% compared to other wet AMD treatments.
- It demonstrated stable best corrected visual acuity (BCVA) and central subfield thickness, a key indicator of retinal health, over 36 weeks.
- The treatment had a well-tolerated safety profile through 36 weeks with no ocular serious adverse events.
In the interview, Dr. Wang also discusses how CLS-AX compares to other TKIs in the development pipeline. You can access the full podcast here.
Dr. Wang serves as Texas Retina’s Director of Clinical Research for Plano and cares for patients in our Dallas Main, Dallas North, Plano and Sherman offices. You can learn more about him here.